BACKGROUND: Laparoscopic Roux-en-Y gastric bypass (LRYGBP) is a commonly performed surgical intervention for morbid obesity. Some authors considered age > or =55 years as a relative contraindication to bariatric surgery. We examined the operative outcomes, weight loss, hospital stay and resolution of co-morbidities in patients > or =55 years old compared with those <55 years old undergoing LRYGBP. METHODS: From Jan 2000 to Feb 2005, 350 LRYGBPs were performed. 48 patients > or =55 years old (13.7%) were compared to the remaining patients. RESULTS: Analysis of the 48 patients > or =55 years old compared with 302 patients <55 revealed no difference in complication rate, although the older patients had a significantly greater percentage of serious complications. Younger patients lost more weight than older patients. Both groups demonstrated resolution of comorbidities, although the difference was not significant. CONCLUSIONS: LRYGBP is safe and well tolerated in morbidly obese patients > or =55 years. The older patients had more serious complications and lost less weight; however, their weight loss and resolution of co-morbidities improved their quality of life. Age should not be a contraindication to bariatric surgery.
BACKGROUND: Laparoscopic Roux-en-Y gastric bypass (LRYGBP) is a commonly performed surgical intervention for morbid obesity. Some authors considered age > or =55 years as a relative contraindication to bariatric surgery. We examined the operative outcomes, weight loss, hospital stay and resolution of co-morbidities in patients > or =55 years old compared with those <55 years old undergoing LRYGBP. METHODS: From Jan 2000 to Feb 2005, 350 LRYGBPs were performed. 48 patients > or =55 years old (13.7%) were compared to the remaining patients. RESULTS: Analysis of the 48 patients > or =55 years old compared with 302 patients <55 revealed no difference in complication rate, although the older patients had a significantly greater percentage of serious complications. Younger patients lost more weight than older patients. Both groups demonstrated resolution of comorbidities, although the difference was not significant. CONCLUSIONS: LRYGBP is safe and well tolerated in morbidly obesepatients > or =55 years. The older patients had more serious complications and lost less weight; however, their weight loss and resolution of co-morbidities improved their quality of life. Age should not be a contraindication to bariatric surgery.
Authors: Edurne Lecumberri; Waeel Krekshi; Pilar Matía; Carlos Hermida; Nuria García de la Torre; Lucio Cabrerizo; Miguel Ángel Rubio Journal: Obes Surg Date: 2011-10 Impact factor: 4.129
Authors: Ruxandra Ciovica; Mark Takata; Eric Vittinghoff; Feng Lin; Andrew M Posselt; Charlotte Rabl; Hubert J Stein; Guilherme M Campos Journal: Obes Surg Date: 2007-12-07 Impact factor: 4.129